The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Development and validation of a prognostic nomogram for progression-free and overall survival in patients with advanced renal cell carcinoma (aRCC) treated with pazopanib.
Michael W. Kattan
Consultant or Advisory Role - GlaxoSmithKline; Merck; Novartis
Cora N. Sternberg
Honoraria - AstraZeneca; AVEO; Boehringer Ingelheim; GlaxoSmithKline; Pfizer
Faisal Mehmud
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Kamalnayan Bhatt
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Debasis Chakrabarti
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Lauren McCann
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Robert John Motzer
Consultant or Advisory Role - Pfizer
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Pfizer